CASI And Cleave Therapeutics Announce Clinical Trial Application Approval For CB-5339 In Patients With Multiple Myeloma In China
CASI focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces that the China National Medical Products Administration (NMPA) has approved the Company’s Clinical Trial Application (CTA) for CB-5339, a first-in-class VCP/p97 inhibitor from Cleave Therapeutics.